Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enlicitide decanoate (MK-0616) extension study in hypercholesterolemia
NCT06492291Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2024
- Primary completion
- Oct 2028
- Modality
- Small Molecules, Cyclic Peptides
- Countries
- 28
01
Overview
A Phase 3 trial of enlicitide in hypercholesterolemia, sponsored by Merck & Co.. Started Aug 2024; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT06492291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06492291.